A5025046655- Heart Failure Treatment and Management
- Cardiovascular Function and Risk Factors
- Cardiac pacing and defibrillation studies
- Pulmonary Hypertension Research and Treatments
- Transplantation: Methods and Outcomes
- Mechanical Circulatory Support Devices
- Diabetes Treatment and Management
- Cardiac electrophysiology and arrhythmias
- Medication Adherence and Compliance
- Cardiac Structural Anomalies and Repair
- Cardiac Arrhythmias and Treatments
- Blood Pressure and Hypertension Studies
- Cardiac Imaging and Diagnostics
- Cardiac Arrest and Resuscitation
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Pancreatic function and diabetes
- Cardiovascular Issues in Pregnancy
- Renal Transplantation Outcomes and Treatments
- Cardiac Valve Diseases and Treatments
- Cardiovascular and exercise physiology
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Cardiac Health and Mental Health
- Cardiac, Anesthesia and Surgical Outcomes
- Health and Medical Education
- Medicine and Dermatology Studies History
Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia
2013-2025
Hospital El Cruce
2013-2025
Pontificia Universidad Católica Argentina
2021-2025
Duke University
2023
AdventHealth Orlando
2023
Fundación Instituto Leloir
2022
Charité - Universitätsmedizin Berlin
2021
University Medical Center
2021
RWTH Aachen University
2021
Boehringer Ingelheim (South Korea)
2021
Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure in patients regardless presence or absence diabetes. More evidence is needed regarding effects these drugs across broad spectrum failure, including those with a markedly reduced ejection fraction.
Sodium–glucose cotransporter 2 inhibitors reduce the risk of hospitalization for heart failure in patients with and a reduced ejection fraction, but their effects preserved fraction are uncertain.
Sodium-glucose cotransporter 2 inhibitors improve outcomes in patients with heart failure reduced ejection fraction, but additional information is needed about whether glycemic status influences the magnitude of their benefits on and renal events.Patients Class II-IV a left ventricular fraction ≤40% were randomized to receive empagliflozin (10 mg daily) or placebo addition recommended therapy. We prespecified comparison effect without diabetes.Of 3730 enrolled, 1856 (50%) had diabetes, 1268...
Heart failure is a global public health problem, affecting large number of individuals from low-income and middle-income countries. REPORT-HF is, to our knowledge, the first prospective registry collecting information on patient characteristics, management, prognosis acute heart using single protocol. The aim this study was investigate differences in 1-year post-discharge mortality according region, country income, income inequality.Patients were enrolled during hospitalisation for 358...
Background The goal of the study was to determine prognostic value nonsustained ventricular tachycardia (NSVT) in total mortality severe congestive heart failure (CHF) and death modes. NSVT is associated with an increased CHF. However, predictive as a marker for sudden or due progressive has not been determined. Methods Results Five hundred sixteen patients from GESICA trial (33.4% NSVT) were initially studied results 24-hour Holter 2 years follow-up. Within years, 87 173 (50.3%) 106 343...
Background: To describe the baseline characteristics of patients with heart failure and preserved left ventricular ejection fraction enrolled in PARAGON-HF trial (Prospective Comparison Angiotensin Receptor Neprilysin Inhibitor With Blocker Global Outcomes HFpEF) comparing sacubitril/valsartan to valsartan reducing morbidity mortality. Methods Results: We report key demographic, clinical, laboratory findings, therapies, 4822 randomized PARAGON-HF, grouped by factors that influence criteria...
EMPEROR-Preserved is an ongoing trial evaluating the effect of empagliflozin in patients with heart failure preserved ejection fraction (HFpEF). This report describes baseline characteristics cohort and compares them enrolled prior HFpEF trials. a phase III randomized, international, double-blind, parallel-group, placebo-controlled which 5988 symptomatic [left ventricular (LVEF) >40%] without type 2 diabetes mellitus (T2DM) have been enrolled. Patients were required to elevated N-terminal...
<h3>Importance</h3> Acute heart failure (AHF) precipitates millions of hospital admissions worldwide, but previous registries have been country or region specific. <h3>Objective</h3> To conduct a prospective contemporaneous comparison AHF presentations, etiologic factors and precipitants, treatments, in-hospital outcomes among global regions through the International Registry to Assess Medical Practice with Longitudinal Observation for Treatment Heart Failure (REPORT-HF). <h3>Design,...
Heart failure (HF) is a global challenge, with lower- and middle-income countries (LMICs) carrying large share of the burden. Treatment for HF reduced ejection fraction (HFrEF) improves survival but often underused. Economic factors might have an important effect on use medicines.This analysis assessed prescription rates doses renin-angiotensin system (RAS) inhibitors, β-blockers, mineralocorticoid receptor antagonists at discharge 6-month follow-up in 8669 patients HFrEF (1458 from low-,...
Use of inotropic agents in patients with heart failure (HF) has been limited by adverse effects on outcomes. However, administration positive inotropes at lower doses and concomitant treatment beta-blockers might increase benefit-risk ratio. We investigated the low inotrope enoximone symptoms, exercise capacity, major clinical outcomes advanced HF who were also treated other guideline-recommended background therapy.The Studies Oral Enoximone Therapy Advanced (ESSENTIAL) programme consisted...
Section:ChooseTop of pageAbstract <<The Pathophysiology RV...Clinical Importance RV...Effect PAH Therapies o...RV Morphology, Function, ...Open Questions and IssuesConclusionsOptimizing Knowledge: Cal...ReferencesCITING ARTICLES
Classe I: Evidências e/ou concordância geral de que o procedimento é benéfico e
Multimorbidity (two or more comorbidities) is common among patients with acute heart failure, but comprehensive global information on its prevalence and clinical consequences across different world regions income levels scarce. This study aimed to investigate the of multimorbidity effect pharmacotherapy prognosis in participants REPORT-HF study.REPORT-HF was a prospective, multicentre, cohort that enrolled adults (aged ≥18 years) admitted hospital primary diagnosis failure from 358 hospitals...
Background. Cytomegalovirus (CMV) infection in recipients of cardiac transplants is associated with higher rates morbidity. A recent phase III trial showed highly significantly (P<0.001) lower CMV the proliferation signal inhibitor everolimus compared to azathioprine (AZA). To better define this association, data on risk factors were collected retrospectively and analyzed. Methods. Data from a multicenter de novo heart transplant (n=634) receiving triple immunosuppressive regimen randomized...